Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.56 - $1.15 $2,632 - $5,405
-4,700 Reduced 28.31%
11,900 $6,000
Q4 2022

Feb 14, 2023

SELL
$0.54 - $21.75 $1,944 - $78,300
-3,600 Reduced 17.82%
16,600 $11,000
Q3 2022

Nov 14, 2022

BUY
$1.23 - $21.9 $3,813 - $67,890
3,100 Added 18.13%
20,200 $29,000
Q2 2022

Aug 15, 2022

SELL
$6.1 - $7.15 $4,270 - $5,005
-700 Reduced 3.93%
17,100 $18,000
Q1 2022

May 16, 2022

SELL
$5.93 - $7.6 $295,314 - $378,480
-49,800 Reduced 73.67%
17,800 $54,000
Q4 2021

Feb 14, 2022

SELL
$6.04 - $8.03 $325,556 - $432,816
-53,900 Reduced 44.36%
67,600 $263,000
Q3 2021

Nov 15, 2021

BUY
$8.02 - $11.0 $879,794 - $1.21 Million
109,700 Added 929.66%
121,500 $640,000
Q2 2021

Aug 16, 2021

BUY
$7.59 - $10.48 $89,562 - $123,664
11,800 New
11,800 $70,000

About Cyclacel Pharmaceuticals, Inc.


  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $6.02M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.